Clinical Trials Logo

Clinical Trial Summary

Phase II trial to study the effectiveness of BMS-247550 in treating patients who have liver or gallbladder cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.


Clinical Trial Description

PRIMARY OBJECTIVES:

I. Determine the objective response rate of patients with hepatobiliary cancer treated with BMS-247550.

II. Determine the toxicity of this drug in these patients. III. Determine the duration of response, median and overall survival, and time to progression in patients treated with this drug.

OUTLINE: This is a multicenter study.

Patients receive BMS-247550 IV over 3 hours on day 1. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed every 6 weeks until disease progression ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00023946
Study type Interventional
Source National Cancer Institute (NCI)
Contact
Status Terminated
Phase Phase 2
Start date August 2001
Completion date November 2009

See also
  Status Clinical Trial Phase
Terminated NCT00787787 - Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer Phase 2
Completed NCT00052364 - Oxaliplatin in Treating Patients With Liver Cancer Phase 2
Completed NCT01229111 - Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers Phase 2
Completed NCT00107536 - Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer Phase 2
Completed NCT02072356 - Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery Early Phase 1
Completed NCT00604721 - Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer Phase 2
Completed NCT00101036 - Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery Phase 2
Completed NCT00028496 - Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer Phase 1
Completed NCT01766219 - CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery Phase 1/Phase 2
Terminated NCT00427973 - AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer Phase 2
Completed NCT00321594 - Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Phase 1/Phase 2
Terminated NCT00087191 - EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer N/A
Completed NCT00006016 - Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery Phase 2
Completed NCT01643499 - Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Phase 1
Completed NCT00639509 - IMC-A12 in Treating Patients With Advanced Liver Cancer Phase 2
Completed NCT00083226 - Doxorubicin and Bortezomib in Treating Patients With Liver Cancer Phase 2
Completed NCT00033462 - Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer Phase 2
Completed NCT01666756 - Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer Phase 1
Active, not recruiting NCT02119065 - Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
Recruiting NCT02557503 - Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE Phase 4